Anlon Healthcare IPO Day 3: GMP, Subscription Status & Investor Outlook – Smart Pick or Risky Bet?

The Anlon Healthcare IPO has reached its third and final day of bidding, drawing strong interest across investor categories. With steady demand and a stable grey market premium (GMP), investors are now weighing whether this IPO is a good long-term opportunity or just a short-term play.

Day 3 Subscription Status

As of the morning session on 29 August 2025, the IPO had received solid participation:

• Overall subscription: ~3.9×
• Retail quota: Subscribed nearly 27×
• Non-Institutional Investors (NIIs): Around 3.2×
• Qualified Institutional Buyers (QIBs): Just over 1×

The enthusiasm from retail investors clearly outpaces institutional demand, showing strong public confidence in the issue.

Grey Market Premium (GMP) Trends

The IPO’s GMP is holding steady at ₹6, suggesting an expected listing price of ₹96–97 per share against the upper price band of ₹91.

This points to a modest premium of 5–6%, which indicates that while blockbuster listing gains may not be on the cards, investors see the IPO as a stable bet.

Expert Opinions – Positives and Risks

Supportive Views

• Analysts highlight strong sectoral tailwinds from government policies like Make in India and PLI schemes, which boost domestic API (Active Pharmaceutical Ingredient) producers.
• The company’s product portfolio and regulatory approvals provide a foundation for future growth.

Cautionary Views

• Heavy reliance on a single manufacturing plant in Rajkot is seen as a risk.
• Valuation looks stretched with a P/E of ~19× and EV/EBITDA of ~16–17×, leaving limited margin of safety.
• Listing gains may be capped due to already high demand from retail bidders.

Brokerage Take
Some research houses have recommended a “Subscribe for Long Term” stance, underlining growth potential but advising against chasing short-term profits alone.

Quick IPO Snapshot

Factor	Detail
Issue Period	Closes on 29 August 2025
Price Band	₹86–91 per share
Overall Subscription	~3.9× (till Day 3 morning)
Retail Subscription	~27×
NII Subscription	~3.2×
QIB Subscription	~1×
GMP	₹6
Likely Listing Price	Around ₹96–97
Analyst View	Good for long-term investors; cautious for short-term traders

Final Verdict – Good or Bad Bet?

• For long-term investors: The IPO could be a smart addition, supported by industry growth drivers and solid fundamentals, though valuations are on the higher side.
• For listing gains: With a GMP of just ₹6, expectations of big first-day profits should be tempered.

In short, Anlon Healthcare IPO looks better suited for patient, long-term investors who believe in India’s expanding pharmaceutical manufacturing story, rather than those chasing quick short-term returns.